Journal profile · Biochemistry & Molecular Biology
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
ISSN 1350-6129 · eISSN 1744-2818 · Informa Healthcare · UNITED STATES · Quarterly · Founded 1994
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 4.97; JCR Q1 (journal website); hybrid open access; APC charged, amount not published; median 104 days to acceptance (90 articles, last 24 months); community-reported acceptance: moderate; 66 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS is published by Informa Healthcare and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Amyloidosis: Diagnosis, Treatment, Outcomes, Alzheimer's disease research and treatments and Parathyroid Disorders and Treatments, together about 57.7% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Amyloid is the official journal of the International Society of Amyloidosis. Amyloid publishes basic and clinical research on amyloids and systemic and localized amyloidosis. The journal's scope and major areas of focus are: Etiology Epidemiology Genetics Pathogenesis, including chemical structure, fibrillogenesis and mechanism of disease Pathology Diagnosis, treatment and prognosis across a broad spectrum of clinical specialties impacted by various amyloid diseases and related disorders. The journal publishes research articles, letters to the Editor, review articles and article commentaries (typically by invitation). Authors can choose to publish gold open access in this journal.
From the journal's Aims & Scope
Research area (LetPub): Biochemistry & Molecular Biology
Editor-in-chief Stefan SchönlandPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Amyloidosis: Diagnosis, Treatment, OutcomesBiochemistry, Genetics and Molecular Biology37.4%
- Alzheimer's disease research and treatmentsMedicine14%
- Parathyroid Disorders and TreatmentsMedicine6.3%
- Dermatological and Skeletal DisordersBiochemistry, Genetics and Molecular Biology4.8%
- Protein Kinase Regulation and GTPase SignalingBiochemistry, Genetics and Molecular Biology3.5%
- Cellular transport and secretionBiochemistry, Genetics and Molecular Biology2.9%
- Multiple Myeloma Research and TreatmentsMedicine2.8%
- Drug Transport and Resistance MechanismsMedicine2.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Medicine, General & Internal | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Medicine, General & Internal | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Medicine, General & Internal | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q1 · best quartile · 2025
- CiteScore Q1 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPMCPubMedEmbaseCurrent ContentsPublisher website
Other: Index Medicus, BIOSIS Previews (Clarivate Analytics), Current Awareness in Biological Sciences, Index Medicus (NLM), ISI Research Alert
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.97LetPub ·
- Impact factor (publisher) 2025
- 5.1Publisher website ·
- 5-year impact factor (publisher) 2025
- 6.3Publisher website ·
- CiteScore 2026-06
- 12.5LetPub ·
- CiteScore (publisher) 2025
- 12.5Publisher website ·
- SJR 2026-06
- 2.19LetPub ·
- SJR (publisher) 2025
- 2.19Publisher website ·
- SNIP 2026-06
- 2.37LetPub ·
- SNIP (publisher) 2025
- 2.37Publisher website ·
- h-index
- 54LetPub ·
- h-index
- 90OpenAlex ·
- i10-index
- 897OpenAlex ·
- 2-year mean citedness
- 3.62OpenAlex ·
- Self-citation rate
- 9.8%LetPub ·
- Share of gold OA articles
- 19.35%LetPub ·
Volume
- Articles per year
- 30LetPub ·
- Downloads per year (publisher)
- 191,000Publisher website ·
- Downloads per year (publisher) 2025
- 191,000Publisher website ·
Articles by year OpenAlex count · 1,892 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 52 | 18 | 17 |
| 2025 | 66 | 19 | 124 |
| 2024 | 57 | 31 | 492 |
| 2023 | 46 | 17 | 350 |
| 2022 | 57 | 21 | 1,678 |
| 2021 | 43 | 16 | 731 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
104 daysMedian, submission to acceptance · P25–P75 72 days – 146 days
- Acceptance to online
- median 13 days (90 articles)
- Submission to online
- median 118 days
- Sample
- 90 articles with submission and acceptance dates (140 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
- Acceptance rate (publisher)
- 17%Publisher website ·
- Submission to first decision
- 12 daysPublisher website ·
- First decision after review
- 34 daysPublisher website ·
- Acceptance to publication
- 19 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted8
- article commentariesThe journal publishes research articles, letters to the Editor, review articles and article commentaries (typically by invitation).Length not stated
- article commentaryThe journal publishes research articles, letters to the Editor, review articles and article commentaries (typically by invitation).Length not stated
- letter to the editorThe journal publishes research articles, letters to the Editor, review articles and article commentaries (typically by invitation).Length not stated
- letters to the editorThe journal publishes research articles, letters to the Editor, review articles and article commentaries (typically by invitation).Length not stated
- research articleThe journal publishes research articles, letters to the Editor, review articles and article commentaries (typically by invitation).Length not stated
- research articlesThe journal publishes research articles, letters to the Editor, review articles and article commentaries (typically by invitation).Length not stated
- review articleThe journal publishes research articles, letters to the Editor, review articles and article commentaries (typically by invitation).Length not stated
- review articlesThe journal publishes research articles, letters to the Editor, review articles and article commentaries (typically by invitation).Length not stated
Policy excerpts from the journal's websiteOpen access
- Open access Open access
Gold open access option available. Model summary
Amyloid is a hybrid open access journal that is part of the Taylor & Francis Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discoverability and readership of y…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Informa Healthcare
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Quarterly
- Founded
- 1994
- ISSN
- 1350-6129
- Electronic ISSN
- 1744-2818
- Society / sponsor
- International Society of Amyloidosis
- Latest issue on the website
- Volume 33, Issue 2 (2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
What CAS zone is AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS in?
In the 2025 upgraded edition of the CAS Journal Ranking, AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS is in Zone 2 of Medicine, and in Zone 2 of the minor category Biochemistry & Molecular Biology / Medicine, General & Internal / Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS?
The latest impact factor listed by LetPub is 4.97; CiteScore 12.5, h-index 90.
How long does peer review take at AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS?
Based on the dates recorded on 90 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 104 days (interquartile range 72–146 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Moderate”; the journal's website gives an acceptance rate of 17%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS in?
The journal's website gives JCR Q1 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 2 of Medicine.
Which databases index AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS?
According to LetPub and DOAJ records, AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, PMC, PubMed, Embase and Current Contents; that list has not been checked against each database.
Is AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS open access, and what is the APC?
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS is a hybrid journal. For open-access publication: APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .